Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosisJune 23, 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidenceJune 21, 2021
EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myelomaConferences, MyelomaJune 14, 2021
EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myelomaConferences, MyelomaJune 13, 2021
EHA 2021 | Patient preferences in myeloma, a qualitative multinational study in myelomaConferences, MyelomaJune 11, 2021
Watch the webinar “COVID-19 vaccines for myeloma patients: what you need to know.”MPE, Myeloma, VideosApril 30, 2021
European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, MyelomaApril 19, 2021
